State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, Guangdong Province, China.
World J Gastroenterol. 2010 Sep 28;16(36):4611-5. doi: 10.3748/wjg.v16.i36.4611.
To determine the role of epidermal growth factor-like repeats and discoidin I-like domains 3 (EDIL3) in pathogenesis of hepatocellular carcinoma (HCC) by investigating the EDIL3 expression in HCC and its prognostic value for HCC.
EDIL3 expression was detected in 101 HCC surgical tissue samples with immunohistochemistry method, and its relation with clinicopathologic features and prognosis of HCC patients was analyzed.
EDIL3 was highly expressed in 48.5% of the HCC patients. Although the EDIL3 expression level did not correlate with any clinicopathological parameters, Kaplan-Meier survival analysis showed that high expression level of EDIL3 resulted in a significantly poor prognosis of HCC patients (log-rank test, P = 0.010). Multivariate Cox's analysis showed that the EDIL3 expression level was a significant and independent prognostic parameter for the overall survival rate of HCC patients (hazard ratio = 1.978, 95% confidence interval = 1.139-3.435, P = 0.015).
High expression level of EDIL3 predicts poor prognosis of HCC patients. EDIL3 may be a potential target of antiangiogenic therapy for HCC.
通过研究肝细胞癌（HCC）中 EDIL3 的表达及其对 HCC 的预后价值，探讨表皮生长因子样重复和盘状结构域 I 样结构域 3（EDIL3）在 HCC 发病机制中的作用。
采用免疫组织化学法检测 101 例 HCC 手术组织标本中 EDIL3 的表达，分析 EDIL3 表达与 HCC 患者临床病理特征及预后的关系。
48.5%的 HCC 患者 EDIL3 呈高表达。尽管 EDIL3 的表达水平与任何临床病理参数均无相关性，但 Kaplan-Meier 生存分析显示 EDIL3 高表达的 HCC 患者预后明显较差（log-rank 检验，P=0.010）。多因素 Cox 分析显示，EDIL3 的表达水平是 HCC 患者总生存率的显著独立预后参数（风险比=1.978，95%置信区间=1.139-3.435，P=0.015）。
EDIL3 高表达预示 HCC 患者预后不良。EDIL3 可能是 HCC 抗血管生成治疗的潜在靶点。
